• Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub
  •  0 items - £0.00
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to primary sidebar
  • Skip to footer

Before Header

  • My account
  •  0 items - £0.00

Action Duchenne

Header Right

  • Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub

PepGen Receives UK CTA Clearance from MHRA to Begin CONNECT2-EDO51 Phase 2 Clinical Trial

You are here: Home / News / Exon skipping news / PepGen Receives UK CTA Clearance from MHRA to Begin CONNECT2-EDO51 Phase 2 Clinical Trial
PepGen Receives UK CTA Clearance from MHRA to Begin CONNECT2-EDO51 Phase 2 Clinical Trial

5 March 2024 by John Marrin

PepGen, a biotech company developing innovative oligonucleotide therapies for severe neuromuscular and neurological diseases, has received approval from the UK regulator (MHRA) to launch the Phase 2 CONNECT2-EDO51 trial. This trial will evaluate PGN-EDO51, a potential treatment for Duchenne muscular dystrophy (DMD) patients who can benefit from exon 51 skipping.

“We are excited to take the next step forward in our development of PGN-EDO51, which we believe to be a potentially transformative investigational candidate for people living with DMD and are pleased the MHRA authorized our CTA. We believe this study, together with the data generated in our ongoing CONNECT1-EDO51 trial, could potentially support accelerated approval of EDO51, subject to alignment with regulators,” said James McArthur, Ph.D., President and CEO of PepGen. “We are grateful to continue our work with the DMD community to develop this therapy.”

The CONNECT2-EDO51 trial remains a multinational, randomised, double-blind, placebo-controlled, multiple ascending dose (MAD) study. It aims to enrol approximately 20 ambulatory and non-ambulatory boys and young men, at least six years old, diagnosed with DMD amenable to exon 51 skipping. Participants will be assigned treatment through randomization, receiving either PGN-EDO51 or a placebo for a treatment period of 24 weeks. Doses will be administered every four weeks, with an initial escalation from 5 mg/kg to 10 mg/kg, potentially reaching higher levels based on safety data from the preceding participant cohorts within the trial. A baseline muscle biopsy will be acquired from each participant, followed by another at week 25. The primary objectives of the trial are to evaluate exon skipping efficiency, dystrophin protein production, and the overall safety and tolerability of PGN-EDO51. All participants will be offered the opportunity to participate in an open-label extension.

Find out more

Would you like to know more about Duchenne muscular dystrophy? Increase your knowledge and understanding of Duchenne with our bite-sized science video series.

Section 1 – Facts about Duchenne muscular dystrophy

Section 2 – Signs and Symptoms of Duchenne muscular dystrophy

Section 3 – Diagnosis of Duchenne muscular dystrophy

Section 4 – Crucial Genetic Terminology

Section 5 – Genetics – Blueprint of Duchenne muscular dystrophy

SAVE THE DATE

Our 2024 Annual International Conference will be held on Friday 8th and Saturday 9th November 2024. The conference brings together families, clinicians, researchers and experts for 2 days of sharing knowledge and experience. It is an amazing opportunity to come together as part of the Duchenne community

Share this:

Category: Exon skipping news, News

Previous Post: « Hope and Determination on Rare Disease Day 2024
Next Post: Taking Control »

Primary Sidebar

From our community

From receiving support to giving it back: Nicola’s journey with Action Duchenne

Written by Nicola Culverhouse “If you had told me two years ago that I would be volunteering for Action Duchenne, I wouldn’t have believed you. Our four-year-old son, Kitto, was diagnosed with Duchenne in August 2024, following 12 months of infections and investigations. He had met all his milestones and we had absolutely no concerns …

Action Duchenne Residential Weekends: “Adventure is still possible”

Action Duchenne Residential Weekends: “Adventure is still possible“ With a Duchenne diagnosis, it often feels that there is an ever-growing list of things that become more difficult. The freedom to choose to take part in activities, to continue hobbies or even just to pop round to a friend’s house changes into something that needs planning, …

Honouring George and Finding Community

Honouring George and Finding Community Remembering George one year on. “If I’d never experienced George having Duchenne, I wouldn’t be half the person I am now. He taught me so much about life. I truly believe that boys with Duchenne are just the most awesome people in the world.”  On Sunday 26th April 2026, Louise Ruddick ran the …

Footer

Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA

0300 102 1762
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

Site Footer

Fundraising Regulator badge with validation link

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852